Author + information
- Caihong Qu,
- Xiaoyan Li,
- Jieming Zhu and
- Ling Tao
Benzbromarone is an inhibitor of CYP2C9 and it may be involved in drug interactions with warfarin dependent on this enzyme for clearance, especially in patients with atrial fibrillation accompanying gout needing warfarin and benzbromarone co-prescription.
68 patients of atrial fibrillation accompanying gout co-administrated with warfarin and benzbromarone during 2014∼2015 in our hospital were investigated, and the patients' coagulation function was collected as well as risk for bleeding was assessed before and after the adding of benzbromarone.
After the adding of benzbromarone, the patients' coagulation function can be enhanced significantly, presenting with prolonged prothrombin time, reduction of prothrombin activity and elevated prothrombin international normalized ratio. The dosage of warfarin need to be adjusted to 42% by average compared to the initial dosage. During the hospitalization, no serious bleeding events occurred because of close monitoring of INR levels.
Clinicians should be aware of the potential interaction between warfarin and benzbromarone mediated by the inhibition of CYP2C9 and adequate consideration must be devoted to the prevention of grave hemorrhagic tendencies when these two drugs are administered concurrently.